Může pomoci zpomalit progresi onemocnění a zmírnit některé symptomy, jako jsou agitace a agresivita. 

Příslušná literatura:

• Ramirez et al. 2005. Prevention of Alzheimer’s disease pathology by cannabinoids. The Journal of Neuroscience 25: 1904-1913.
• Israel National News. December 16, 2010. “Israeli research shows cannabidiol may slow Alzheimer’s disease.”
• Eubanks et al. 2006. A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Molecular Pharmaceutics 3: 773-777.
• Marchalant et al. 2007. Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation, Neuroscience 144: 1516-1522.
• Hampson et al. 1998. Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences 95: 8268-8273
• Science News. June 11, 1998. “Marijuana chemical tapped to fight strokes.”
• Campbell and Gowran. 2007. “Alzheimer’s disease; taking the edge off with cannabinoids?” British Journal of Pharmacology 152: 655-662.
• Walther et al. 2006. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Physcopharmacology 185: 524-528.
• BBC News. August 21, 2003. “Cannabis lifts Alzheimer’s appetite.

Doporučený poměr v následujícím odkazu:

Potenciál ke zmírnění symptomů, prodloužení života a zlepšení kvality života pacientů.

Příslušná literatura:

• Amtmann et al. 2004. “Survey of cannabis use in patients with amyotrophic lateral sclerosis.” The American Journal of Hospice and Palliative Care 21: 95-104.
• Raman et al. 2004. “Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid.” Amyotrophic
  Lateral Sclerosis & Other Motor Neuron Disorders 5: 33-39.
• Weydt et al. 2005. “Cannabinol delays symptom onset in SOD1 transgenic mice without affecting survival.” Amyotrophic Lateral Sclerosis
  & Other Motor Neuron Disorders 6: 182-184.Bilsland et al. 2006. “Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice.” The FASEB Journal 20: 1003-1005.
• Carter et al. 2010. “Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials.” American
  Journal of Hospice & Palliative Medicine 27: 347-356.

Doporučený poměr v následujícím odkazu:

Může pomoci stabilizovat krevní cukr, snížit arteriální záněty a zlepšit cirkulaci.

Příslušná literatura:

• Croxford and Yamamura. 2005. “Cannabinoids and the immune system: Potential for the treatment of inflammatory diseases.” Journal
  of Neuroimmunology 166: 3-18. Lu et al. 2006. “The cannabinergic system as a target for anti-inflammatory therapies.” Current Topics
  in Medicinal Chemistry 13: 1401-1426.
• Weiss et al. 2006. “Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.” Autoimmunity 39: 143-151.
• Wargent et al. 2013. “The cannabinoid ∆9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.”
  Nutrition & Diabetes 3.
• El-Remessy et al. 2006. “Neuroprotective and blood-retinal barrier preserving effects of cannabidiol in experimental diabetes.” American
  Journal of Pathology 168: 235-244.
• Dogrul et al. 2004. “Cannabinoids block tactile allodynia in diabetic mice without attenuation of its antinociceptive effect.” Neuroscience
  Letters 368: 82-86.Ulugol et al. 2004. “The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats.” Neuroscience Letters 71: 167-170
• Rajesh et al. 2010. “Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.” Journal of the American College of Cardiology 56: 2115-2125.
• Rajavashisth et al. 2012. “Decreased prevalence of diabetes in marijuana users.” BMJ Open 2
• Penner et al. 2013. “Marijuana use on glucose, insulin, and insulin resistance among US adults.” American Journal of Medicine 126: 583-589. Strat and Foll. 2011. “Previous observational data has similarly reported that the prevalence of obesity in the general population is sharply lower among marijuana consumers than it is among nonusers.” American Journal of Epidemiology 174: 929-933.

Kanabinoidy mohou pomoci zmírnit svalové křeče a bolesti.

Příslušná literatura:

• Chatterjee et al. 2002. “A dramatic response to inhaled cannabis in a woman with central thalamic pain and dystonia.” The Journal
  of Pain and Symptom Management 24: 4-6.
• Roca et al. 2004. “Cannabis sativa and dystonia secondary to Wilson’s disease.” Movement Disorders 20: 113-115.
• Jabusch et al. 2004. “Delta-9-tetrahydrocannabinol improves motor control in a patient with musician’s dystonia.” (PDF) Movement
  Disorders 19: 990-991.
• Fox et al. 2002. “Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the
  treatment of dystonia.” Movement Disorders 17: 145-149.
• Richter et al. 2002. “Effects of pharmacological manipulations of cannabinoid receptors on severe dystonia in a genetic model of paroxysmal dyskinesia.” European Journal of Pharmacology 454: 145-151.
• Consroe et al. 1986. “Open label evaluation of cannabidiol in dystonic movement disorders.” International Journal of Neuroscience
  30: 277-282.Richter et al. 1994. “(+)-WIN 55212-2, a novel cannabinoid agonist, exerts antidystonic effects in mutant dystonic hamsters.”
  European Journal of Pharmacology 264: 371-377.

CBD je prokazatelně účinné v redukci frekvence a intenzity záchvatů.

Příslušná literatura:

• Editorial. 2012. “Marijuana for epilepsy: winds of change.” Epilepsy & Behavior 29: 435-436
• Saundra Young, CNN.com. August 7, 2013. “Marijuana stops child‘s severe seizures.”
• Porter and Jacobson. 2013. “Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.”
  Epilepsy & Behavior 29: 574-577.
• Susan Livio, New Jersey Star-Ledger. December 6, 2013. “FDA-approved medical marijuana clinical trial gets underway next month
  for kids with epilepsy.”

Doporučený poměr v následujícím odkazu:

Konopí může nabízet úlevu od bolesti a zlepšení spánku.

Příslušná literatura:

• Swift et al. 2005. “Survey of Australians using cannabis for medical purposes.” Harm Reduction Journal 4: 2-18.Ware et al. 2005. “The medicinal use of cannabis in the UK: results of a nationwide survey.”International Journal of Clinical Practice 59: 291-295.
• Dale Gieringer. 2001. “Medical use of cannabis: experience in California.” In: Grotenhermen and Russo (Eds). Cannabis and CannabiQRLGV3KDUPDFRORJ\7R[LFRORJ\DQG7KHUDSHXWLF3RWHQWLDO.” New York: Haworth Press: 153- 170.Gorter et al. 2005. Medical use of cannabis in the Netherlands.” Neurology 64: 917-919.
• Schley et al. 2006. “Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief.” Current Medical Research and Opinion 22: 1269-1276
• Skrabek et al. 2008. “Nabilone for the treatment of pain in fibromyalgia.” The Journal of Pain 9: 164-173.
• Ware et al. 2010. “The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial.” Anesthesia and Analgesia 110: 604-610.
• Fiz et al. 2011. “Cannabis use in patients with fibromyalgia: Effect on symptoms relief and health-related quality of life.” PLoS One 6.
• Burns and Ineck. 2006. “Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain.” The Annals of Pharmacotherapy 40: 251-260.David Secko. 2005. “Analgesia through endogenous cannabinoids.”
• Lynch and Campbell. 2011. op. cit.
• Ethan Russo. 2004. “Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?” Neuroendocrinology Letters 25: 31-39.

Doporučený poměr v následujícím odkazu:

Preklinické studie ukazují na potenciál kanabinoidů indukovat smrt rakovinných buněk a inhibovat růst nádorů.

Příslušná literatura:

• Guzman et al. 1998. “Delta-9-tetrahydrocannabinol induces apoptosis in C6 glioma cells.” FEBS Letters 436: 6-10.
• Guzman et al. 2000. “Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation.” Nature Medicine 6: 313-319.
• Guzman et al. 2003. “Inhibition of tumor angiogenesis by cannabinoids.” The FASEB Journal 17: 529-531.
• Massi et al. 2004. “Antitumor effects of cannabidiol, a non-psychotropic cannabinoid, on human glioma cell lines.”
• Guzman et al. 2004. “Cannabinoids inhibit the vascular endothelial growth factor pathways in gliomas.” (PDF) Cancer Research 64: 5617-5623.
• Allister et al. 2005. “Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.” Journal of Neurooncology 74: 31-40.
• Torres et al. 2011. “A combined preclinical therapy of cannabinoids and Temozolomide against glioma.” Molecular Cannabis Therapeutics 10: 90.
• Guzman et al. 2006. “A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.” British Journal of Cancer
• Parolaro and Massi. 2008. “Cannabinoids as a potential new drug therapy for the treatment of gliomas.”
• Galanti et al. 2007. “Delta9-Tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells.” Acta Oncologica 12: 1-9.
• Calatozzolo et al. 2007. “Expression of cannabinoid receptors and neurotrophins in human gliomas.” Neurological Sciences 28: 304-310.
• Foroughi et al. 2011. “Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas -- possible role of cannabis inhalation.” Child’s Nervous System 27: 671-679.
• Cafferal et al. 2006. “Delta-9-Tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.” Cancer Research 66: 6615-6621.Di Marzo et al. 2006. “Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.”
• De Petrocellis et al. 1998. “The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.” Proceedings of the National Academy of Sciences of the United States of America 95: 8375-8380.
• McAllister et al. 2007. “Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.” Molecular Cancer Therapeutics 6: 2921-2927.
• Cafferal et al. 2010. “Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.” Molecular Cancer 9: 196.
• Sarfaraz et al. 2005. “Cannabinoid receptors as a novel target for the treatment of prostate cancer.” Cancer Research 65: 1635-1641.
• Mimeault et al. 2003. “Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines.” Prostate 56: 1-12.
• Ruiz et al. 1999. “Delta-9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism.” FEBS Letters 458: 400-404.
• Ramos and Bianco. 2012. “The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications.” Journal of Urology 28: 9-14.
• Pastos et al. 2005. “The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase-2.” Gut 54: 1741-1750.Aviello et al. 2012. “Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.” Journal of Molecular Medicine.
• Casanova et al. “Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.” 2003. Journal of Clinical Investigation 111: 43-50.
• Powles et al. 2005. “Cannabis-induced cytotoxicity in leukemic cell lines.” Blood 105: 1214-1221Jia et al 2006. “Delta-9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemic T cells in regulated by translocation of Bad to mitochondria.” Molecular Cancer Research 4: 549-562.
• Liu et al. 2008. “Enhancing the in vitro cytotoxic activity of A9-tetrahydrocannabinol in leukemic cells through a combinatorial approach.” Leukemia and Lymphoma 49: 1800-1809.
• Scott et al. 2013. “Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules” Anticancer Research 33: 4373-4380.
• Manuel Guzman. 2003. “Cannabinoids: potential anticancer agents.” (PDF) Nature Reviews Cancer 3: 745-755.Marcu et al. 2010. “Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.” Molecular Cancer Therapeutics 9: 180-189.
• Guzman. 2003 op. cit.Preet et al. 2008. “Delta-9-tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo.” Oncogene 10: 339-346.
• Manuel Guzman. 2003. “Cannabinoids: potential anticancer agents.” (PDF) Nature Reviews Cancer 3: 745-755.
• Baek et al. 1998. “Antitumor activity of cannabigerol against human oral epitheloid carcinoma cells.” Archives of Pharmacal Research:21: 353-356.
• Carracedo et al. 2006. “Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes.” Cancer Research 66: 6748-6755.Michalski et al. 2008. “Cannabinoids in pancreatic cancer: correlation with survival and pain.” International Journal of Cancer 122: 742-750.
• Ramer and Hinz. 2008. “Inhibition of cancer cell invasion by cannabinoids via increased cell expression of tissue inhibitor of matrix metalloproteinases-1.” Journal of the National Cancer Institute 100: 59-69.
• Whyte et al. 2010. “Cannabinoids inhibit cellular respiration of human oral cancer cells.” Pharmacology 85: 328-335.
• Leelawat et al. 2010. “The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: antiinvasion activity at low concentration and apoptosis induction at high concentration.” Cancer Investigation 28: 357-363.
• Gustafsson et al. 2006. “Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and WIN 55,212 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma.” Molecular Pharmacology 70: 1612-1620. Gustafsson et al. 2008. “Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation.” International Journal of Cancer 123: 1025-1033.
• Natalya Kogan. 2005. “Cannabinoids and cancer.” Mini-Reviews in Medicinal Chemistry 5: 941-952.Sarafaraz et al. 2008. “Cannabinoids for cancer treatment: progress and promise.” Cancer Research 68: 339-342.
• Wai Man Liu et al. 2013 “Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules.” Anticancer Research.

Doporučený poměr v následujícím odkazu:

Pomáhá v boji proti nevolnosti, ztrátě chuti k jídlu a bolesti spojené s léčbou a onemocněním.

Příslušná literatura:

• Woolridge et al. 2005. “Cannabis use in HIV for pain and other medical symptoms.” Journal of Pain Symptom Management 29: 358-367.
• Prentiss et al. 2004. “Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting.” 
• Braitstein et al. 2001. “Mary-Jane and her patients: sociodemographic and clinical characteristics of HIVpositive individuals using medical marijuana and antiretroviral agents.” AIDS 12: 532-533.
• Ware et al. 2003. “Cannabis use by persons living with HIV/AIDS: patterns and prevalence of use.” Journal of Cannabis Therapeutics 3: 3-15.
• Belle-Isle and Hathaway. 2007. “Barriers to access to medical cannabis for Canadians living with HIV/AIDS.” AIDS Care 19: 500-506.
• de Jong et al. 2005. “Marijuana use and its association with adherence to antiretroviral therapy among HIV infected persons with moderate to severe nausea.” 
• Chao et al. 2008. “Recreational drug use and T lymphocyte subpopulations in HIV-uninfected and HIV infected men.” Drug and Alcohol Dependence 94:165-171
• Abrams et al. 2003. “Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.” Annals of Internal Medicine 139: 258-266.Fogarty et al. 2007. “Marijuana as therapy for people living with HIV/AIDS: social and health aspects.” AIDS Care 19: 295-301.
• Haney et al. 2007. “Dronabinol and marijuana in HIV-positive marijuana smokers: caloric intake, mood and sleep.”
• Abrams et al. 2007. “Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial.” Neurology 13: 68(7): 515-21.
• Ellis et al. 2008. “Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial.” op. cit.
• Riggs et al. 2012. “A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men.” Brain Research 1431: 46-52.
• Molina et al. 2011. “Cannabinoid administration attenuates the progression of simian immunodeficiency virus.” AIDS Research and Human Retroviruses 27: 585-592.
• Ramirez et al. 2013. “Attenuation of HIV-1 replication in macrophages by cannabinoid receptor 2 agonists.” Journal of Leukocyte Biology 93: 801-810:.
• Fogarty et al. 2007. op. cit.
• EurekAlert!. “Temple scientists weaken HIV infection in immune cells using synthetic agents.” May 1, 2013.

Doporučený poměr v následujícím odkazu:

Může pomoci zlepšit motorické funkce a snížit neurodegenerativní poškození.

Příslušná literatura:

• Consroe et al. 1991. “Controlled clinical trial of cannabidiol in Huntington’s disease.” 3KDUPDFRORJ\ %LRFKHPLVWU\ DQG %HKDYLRU
  40: 701-708.
• Luvone et al. 2009. “Cannabidiol: a promising drug for neurodegenerative disorders?” CNS Neuroscience & Therapeutics 15: 65-75.[3]
  Sagredo et al. 2012. “Cannabinoids: novel medicines for the treatment of Huntington’s disease.” Recent Patents on CNS Drug Discovery
  7: 41-48.
• Sagredo et al. 2011. “Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease.”
  Journal of Neuroscience Research 89: 1509-1518.

Konopí může mít pozitivní vliv na snížení krevního tlaku.

Příslušná literatura:

• Franjo Grotenhermen. 2006. “Clinical pharmacodynamics of cannabinoids. In Russo et al (Eds) Handbook of Cannabis Therapeutics. Binghampton, New York: Haworth Press.
• Batkai et al. 2004. “Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension.” Circulation 110: 1996-220.Pacher et al. 2005. “Blood pressure regulation by endocannabinoids and their receptors.” (PDF) Neuropharmacology 48: 1130-1138.
• Kunos et al. 2000. “Endocannabinoids as cardiovascular modulators.” Chemistry and Physics of Lipids 108: 159-168.
• Reese Jones. 2002. “Cardiovascular system effects of marijuana.” 
• Ribuot et al. 2005. “Cardiac and vascular effects of cannabinoids: toward a therapeutic use?” Annales de Cardiologie et d’Angeiologie 54: 89-96.
  Steven Karch. 2006. “Cannabis and cardiotoxicity.” )
• Rodondi et al. 2006. “Marijuana use, diet, body mass index and cardiovascular risk factors.” American Journal of Cardiology 98: 478-484.
• Steffens and Mach. 2006. “Towards a therapeutic use of selective CB2 cannabinoid receptor ligands for atherosclerosis.” Future Cardiology 2: 49-53
• Steffens et al. 2005. “Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.” Nature 434: 782-786.
• Steffens and Mach. 2006. “Cannabinoid receptors in atherosclerosis.” Current Opinion in Lipidology 17: 519-526.
• Thomas et al. 2014. “Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know.” American Journal of Cardiology 113: 187-190.

Doporučený poměr v následujícím odkazu:

Efektivní v léčbě různých typů chronické bolesti, včetně neuropatické bolesti.

Příslušná literatura:

• Abrams et al. 2007. “Cannabis in painful HIV-associated sensory neuropathy: a randomized placebocontrolled trial.” Neurology 68: 515-521.Ellis et al. 2008. “Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial.” Neuropsychopharmacology 34: 672-80.
• Wallace et al. 2007. “Dose-dependent effects of smoked cannabis on Capsaicin-induced pain andhyperalgesia in healthy volunteers.” Anesthesiology 107: 785-796.
• Wilsey et al. 2008. “A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.” Journal of Pain 9:506-521.
• Ware et al. 2010. “Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.” CMAJ 182: 694-701.
• Cooper et al. 2013. “Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers.” Neuropsychopharmacology 38: 1984-1992.
• Lynch and Campbell. 2011. “Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.” British Journal of Clinical Pharmacology 72: 735-744.
• Sunil Aggerwal. 2012. “Cannabinergic pain medicine: a concise clinical primer and survey of randomized controlled trial results.” The Clinical Journal of Pain [E-pub ahead of print].
• Comelli et al. 2008. “Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain.” Phytotherapy Research 22: 1017-1024.
• Johnson et al. 2009. “Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety and tolerability of THC: CBD extract in patients with intractable cancer-related pain.” Journal of Symptom Management 39: 167-179.
• Abrams et al. 2011. “Cannabiniod-opioid interaction in chronic pain.” Clinical Pharmacology & Therapeutics 90: 844-851.
• Wilsey et al. 2013. “Low-dose vaporized cannabis significantly improves neuropathic pain.” The Journal of Pain 14: 136-148.
• Mark Collen. 2012. “Prescribing cannabis for harm reduction.” Harm Reduction Journal 9: 1.

Doporučený poměr v následujícím odkazu:

 a 

Kanabinoidy mohou pomoci zlepšit kontrolu močového měchýře.

Příslušná literatura:

• Wade et al. 2003. “A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.” Clinical Rehabilitation 17: 21-29.
• Brady et al. 2004. “An open label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis.” Multiple Sclerosis 10: 425-433.
• Freeman et al. 2006. “The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomized placebo-controlled trial.” The International Urogynecology Journal 17: 636-641.
• University of Pittsburgh Medical Center Press Release. May 21, 2006. “Marijuana-derived drug suppresses bladder pain in animal models.”
• Kalsi and Fowler. 2005. “Therapy insight: bladder dysfunction associated with multiple sclerosis.” Nature Clinical Practice Neurology 2: 492-501.

Kanabinoidy mají antibakteriální účinky proti MRSA.

Příslušná literatura:

• Klevens et al. 2007. “Invasive methicillin-resistant Staphylococcus aureus infections in the United States.” Journal of the American Medical Association 298: 1763-1771.
• Appendino et al. 2008. “Antibacterial cannabinoids from Cannabis sativa: a structure study.” Journal of Natural Products 71: 1427-1430.
• Radwan et al. 2008. “Non-cannabinoid constituents from a high potency Cannabis sativa variety.” Phytochemistry 69: 26727-2633

Může pomoci ulevit od symptomů Crohnovy choroby a ulcerózní kolitidy.

Příslušná literatura:

• Lal et al. 2011. “Cannabis use among patients with inflammatory bowel disease.” European Journal of Gastroenterology & Hepatology 23: 891-896.
• Gahlinger, Paul M. 1984. “Gastrointestinal illness and cannabis use in a rural Canadian community.” Journal of Psychoactive Drugs 16: 263-265.Swift et al. 2005. “Survey of Australians using cannabis for medical purposes.” Harm Reduction Journal 4: 2-18.
• Baron et al. 1990. “Ulcerative colitis and marijuana.” Annals of Internal Medicine 112: 471.Jeff Hergenrather. 2005. “Cannabis alleviates symptoms of Crohn’s disease.” O’Shaughnessy’s 2: 3.
• Massa and Monory. 2006. “Endocannabinoids and the gastrointestinal tract.” Journal of Endocrinological Investigation 29 (Suppl): 47-57.
• Roger Pertwee. 2001. “Cannabinoids and the gastrointestinal tract.” Gut 48: 859-867.
• DiCarlo and Izzo. 2003. “Cannabinoids for gastrointestinal diseases: potential therapeutic applications.” ([SHUW2SLQLRQRQ,QYHVWLJDWLonal Drugs 12: 39-49.
• Lehmann et al. 2002. “Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs.” Gastroenterology 123: 1129-1134.
• Wright et al. 2005. “Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing.” Gastroenterology 129: 437-453.

Doporučený poměr v následujícím odkazu:

Kanabinoidy mohou podporovat tvorbu kostí a pomoci předcházet ztrátě kostní hmoty.

Příslušná literatura:

• Vratislav Schrieber. 1995. “Endocrinology 1994-1995.” ýDVRSLVOpNDĜĤþHVNêFK 134: 535-536.
• Ofek et al. 2006. “Peripheral cannabinoid receptor, CB2, regulates bone mass.” Proceedings of the National Academy of Sciences of the United States of America 103: 696-701.
• Itia Bab. 2007. “Regulation of skeletal remodeling by the endocannabinoid system.” Annals of the New York Academy of Sciences 1116: 414-422.
• Bab et al. 2009. “Cannabinoids and the skeleton: from marijuana to reversal of bone loss.” Annals of Medicine 41: 560-567.

Doporučený poměr v následujícím odkazu:

Pomáhá zmírňovat tremor a další motorické symptomy.

Příslušná literatura:

• Finseth et al. 2015. “Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson’s disease patients in Colorado.” Evidence-Based Complementary and Alternative Medicine. In Print.Venderova et al. 2002. “Survey on cannabis use in Parkinson‘s disease: Subjective improvement of motor symptoms.” Movement Disorders 19: 1102-1106.
• Lotan et al. 2014. “Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.” Clinical Neuropharmacology 37: 41-44.
• Chagas et al. 2014. “Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson‘s disease patients: a case series.” Journal of Clinical Pharmacy and Therapeutics 39: 564-566.
• Chagas et al. 2014. “Effects of cannabidiol in the treatment of patients with Parkinson‘s disease: an exploratory double-blind trial.” Journal of Psychopharmacology 28: 1088-1098.
• Zuardi et al. 2009. “Cannabidiol for the treatment of psychosis in Parkinson‘s disease.” Journal of Psychopharmacology 23: 979-983.

Doporučený poměr v následujícím odkazu:

Může pomoci regulovat strach a úzkost spojené s PTSP.

Příslušná literatura:

• Nuemeister et al. 2013. “Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study.” Molecular Psychiatry 18: 1034-1040
• Passie et al. “Mitigation of post-traumatic stress symptoms by cannabis resin: A review of the clinical and neurobiological evidence.” Drug Testing and Analysis 4: 649-659
• Greer et al. 2014. “PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program.” Journal of Psychoactive Drugs 46: 73-77.
• Medscape. December 15, 2004. “Medical marijuana may worsen PTSD symptoms, increase violence.”
• Roitman et al. 2014. “Preliminary, open-label, pilot study of add-on oral delta-9-tetrahydrocannabinol in chronic post-traumatic stress disorder.” Clinical Drug Investigation 34: 587-591.
• Cameron et al. 2014. “Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation.” Journal of Clinical Psychopharmacology 34: 559-564.
• Fraser G. 2009. “The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD).” CNS Neuroscience & Therapeutics 15: 84-88.

Doporučený poměr v následujícím odkazu:

Konopí může nabízet protizánětlivé účinky a úlevu od bolesti.

Příslušná literatura:

• Swift et al. 2005. “Survey of Australians using cannabis for medical purposes.” Harm Reduction Journal 4: 2-18.
• Ware et al. 2005. “The medicinal use of cannabis in the UK: results of a nationwide survey.” International Journal of Clinical Practice 59: 291-295.
• Blake et al. 2006. “Preliminary assessment of the efficacy, tolerability and safety of a cannabis medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.” Rheumatology 45: 50-52.
• No author. 2003. “Cannabis-based medicines.” Drugs in Research and Development 4: 306-309.
• Malfait et al. 2000. “The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine.” Journal of the Proceedings of the National Academy of Sciences 97: 9561-9566.
• Sumariwalla et al. 2004. “A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis.” Arthritis & Rheumatism 50: 985-998.
• Croxford and Yamamura. 2005. “Cannabinoids and the immune system: potential for the treatment of inflammatory diseases.” Journal of Neuroimmunology 166: 3-18

Doporučený poměr v následujícím odkazu:

Pomáhá zmírnit svalovou spasticitu a bolest.

Příslušná literatura:

• Corey-Bloom et al. 2012. “Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebocontrolled trial.” CMAJ 10: 1143-1150.
• Clark et al. 2004. “Patterns of cannabis use among patients with multiple sclerosis.” Neurology 62: 2098-2010.
• Reuters News Wire. August 19, 2002. “Marijuana helps MS patients alleviate pain, spasms.
• Pryce et al. 2003. “Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.” Brain 126: 2191-2202.
• de Lago et al. 2012. “Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB(1) receptor-mediated anti-inflammatory effects.” Neuropharmacology [E-pub ahead of print].
• Killestein et al. 2003. “Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis.” Journal of Neuroimmunology 137: 140-143.
• Wade et al. 2006. “Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms of multiple sclerosis.” Multiple Sclerosis 12: 639-645.
• Rog et al. 2007. “Oromucosal delta-9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.”Clinical Therapeutics 29: 2068-2079.

Doporučený poměr v následujícím odkazu:

Může zlepšit kvalitu spánku a snížit frekvenci apnoických epizod.

Příslušná literatura:

• Carley et al. 2002. “Functional role for cannabinoids in respiratory stability during sleep.” Sleep 25: 399-400.
• Prasad et al. 2013. “Proof of concept trial of dronabinol in obstructive sleep apnea.” Frontiers in Psychiatry [online journal only].

Doporučený poměr v následujícím odkazu:

Konopí může pomoci zmírnit chronické svědění.

Příslušná literatura:

• Neff et al. 2002. “Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease.” American Journal of Gastroenterology 97: 2117-2119.
• Dvorak et al. 2003. “Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin.”
• Dvorak et al. 2003. “Cannabinoid agonists attenuate capsaicin-induced responses in human skin.” Pain 102: 283-288.
• Szepietowski et al. 2005. “Efficacy and tolerance of the cream containing structured physiological lipid endocannabinoids in the treatment of uremic pruritus: a preliminary study.” Acta Dermatovenerologic Croatica (Croatia) 13: 97-103.
• Paus et al. 2006. “Frontiers in pruritus research: scratching the brain for more effective itch therapy.” Journal of Clinical Investigation 116: 1174-1185.

Kanabinoidy mohou pomoci kontrolovat tiky a impulsivní výkřiky.

 Příslušná literatura:

• Muller-Vahl et al. 1999. “Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol.” American Journal of Psychiatry 156: 495.
• Muller-Vahl et al. 2002. “Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol (THC): a randomized crossover trial.” Pharmacopsychiatry 35: 57-61.
• Muller-Vahl et al. 2001. “Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance.” Pharmacopsychiatry 34: 19-24.
• Muller-Vahl et al. 2003. “Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.” Journal of Clinical Psychiatry 64: 459-65.
• Muller-Vahl et al. 2003. “Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance.” Neuropsychopharmacology 28: 384-8
• Kirsten Muller-Vahl. 2003. “Cannabinoids reduce symptoms of Tourette’s syndrome.” 
• Kirsten Muller-Vahl. 2013. “Treatment of Tourette syndrome with cannabinoids.” Behavioral Neurology 27: 119-124

Doporučený poměr v následujícím odkazu:

Může pomoci zmírnit vedlejší účinky léčby a zlepšit virovou odezvu.

Příslušná literatura:

• Sylvestre et al. 2006. “Cannabis use improves retention and virological outcomes in patients treated for hepatitis C.” European Journal of Gastroenterology & Hepatology. 18: 1057-1063.
• Zamora-Valdes et al. 2005. “The endocannabinoid system in chronic liver disease.” (PDF) Annals of Hepatology 4: 248-254.Gabbey et al. 2005. “Endocannabinoids and liver disease – review.” Liver International 25: 921-926.
• Lavon et al. 2003. “A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation.” Molecular Pharmacology 64: 1334-1344
• Hezode et al. 2005. “Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42: 63-71.Ishida et al. 2008. “Influence of cannabis use on severity of hepatitis C disease.” Clinical Gastroenterology and Hepatology 6: 69-75.
• Parfieniuk and Flisiak. 2008. “Role of cannabinoids in liver disease. ” World Journal of Gastroenterology 14: 6109-6114.
• Brunet et al. 2013. “Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis.” Clinical Infectious Diseases 57: 663-670.
• Fischer et al. 2006. “Treatment for hepatitis C virus and cannabis use in illicit drug user patients: implications and questions.” European Journal of Gastroenterology & Hepatology. 18: 1039-1042.
• Hezode et al. 2008. “Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.”Gastroenterology 134: 432-439.Purohit et al. 2010. “Role of cannabinoids in the development of fatty liver (steatosis).” The AAPS Journal 12: 233-237